MRNS Marinus Pharmaceuticals Inc.

3.67
-0.14  -4%
Previous Close 3.81
Open 3.82
Price To Book 3.34
Market Cap 192,875,474
Shares 52,554,625
Volume 471,602
Short Ratio
Av. Daily Volume 514,572

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data due by the end of 3Q 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Data due first half of 3Q 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 top-line data due mid-2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Data due first half of 3Q 2019.
Ganaxolone - oral (Amaryllis)
Postpartum depression
Phase 3 top-line data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy

Latest News

  1. Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
  2. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
  3. Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
  4. Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
  5. Marinus Pharmaceuticals: 1Q Earnings Snapshot
  6. Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
  7. How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
  8. Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
  9. Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
  10. Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
  11. Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
  12. Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
  13. Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why
  14. Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
  15. Main Line biopharm CEO stepping down
  16. Marinus Announces Leadership Transition
  17. Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
  18. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  19. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  20. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019